Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1990;116(1):1-7.
doi: 10.1007/BF01612631.

Local and regional immunotherapy of cancer with interleukin 2

J Bubeník  1
Affiliations
Review

Local and regional immunotherapy of cancer with interleukin 2

J Bubeník. J Cancer Res Clin Oncol. 1990.

Abstract

The results obtained in preclinical systems as well as the first clinical trials suggest that local IL-2 immunotherapy may represent a novel approach to the treatment of some neoplasms. However, the experimental results should be confirmed and substantially extended before definitive conclusions can be drawn. We hope that the data and considerations discussed in this article will facilitate thoughts concerned with future clinical IL-2 trials and be instrumental in the optimization of IL-2 cancer immunotherapy.

PubMed Disclaimer

References

    1. Adler A, Stein JA, Kedar E, Naor D, Weiss DW (1984) Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod 3:491 - PubMed
    1. Brandhuber BJ, Boone T, Kenney WC, McKay DB (1987) Three-dimensional structure of interleukin-2. Science 238:1707 - PubMed
    1. Bubeník J (1989a) Tumor inhibitory effects of regional interleukin 2 administration and the role of lymphokine-activated killer cells. In: Lotzová E, Herberman R (eds) Role of interleukin-2 activated killer cells in cancer. CRC, Boca Raton, Florida (in press)
    1. Bubeník J (1989b) Local immunotherapy of cancer with interleukin 2. Immunol Lett 21:267 - PubMed
    1. Bubeník J, Indrová M (1987a) The antitumour efficacy of human recombinant interleukin 2: correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to the IL-2 immunotherapy in vivo. Cancer Immunol Immunother 24:269 - PMC - PubMed

LinkOut - more resources